Genflow Biosciences on breakthrough biotech projects and priorities for 2025

Proactive - Interviews for investors

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s strong progress in 2024 and its priorities for 2025. Leire outlined four major projects: the MASH project targeting liver disease, advancements in sarcopenia, research on Werner syndrome through synthetic organ development, and the innovative life-extension project for dogs. The MASH project is in its preclinical phase, focusing on demonstrating efficacy and ensuring compliance with manufacturing standards to progress toward clinical trials. Sarcopenia research, addressing age-related muscle loss, aims to restore mitochondrial function, potentially benefiting the immune system and brain health. Werner syndrome research leverages synthetic liver models, enabling more accurate preclinical results for clinical trials. Additionally, the company is conducting groundbreaking trials on life-extension solutions for dogs. Using a cohort of ageing dogs, Genflow aims to determine the efficacy of its treatment by late 2025 or early 2026. Leire expressed enthusiasm about these projects and the potential they hold for both humans and animals. To learn more about Genflow’s innovations, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for updates on groundbreaking biotech research. #GenflowBiosciences #BiotechInnovation #LifeExtension #MASHProject #SarcopeniaResearch #WernerSyndrome #DogHealth #Biotech2025 #MitochondriaResearch #ClinicalTrials